Article
Clinical Neurology
Max E. Adrichem, Ilse M. Lucke, Alexander F. J. E. Vrancken, H. Stephan Goedee, Luuk Wieske, Marcel G. W. Dijkgraaf, Nicol C. Voermans, Nicolette C. Notermans, Catharina G. Faber, Leo H. Visser, Krista Kuitwaard, Pieter A. van Doorn, Ingemar S. J. Merkies, Rob J. de Haan, Ivo N. van Schaik, Filip Eftimov
Summary: The study aimed to determine whether intravenous immunoglobulin withdrawal is non-inferior to continuing treatment and to assess the frequency of overtreatment in patients. Findings showed that intravenous immunoglobulin withdrawal did not meet the non-inferiority criteria, but a significant proportion of patients could safely stop treatment and most relapsed patients were quickly restabilized.
Article
Clinical Neurology
Matthew Silsby, Alessandro F. Fois, Con Yiannikas, Karl Ng, Matthew C. Kiernan, Victor S. C. Fung, Steve Vucic
Summary: This study aimed to evaluate tremor in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and test the hypothesis that tremor occurs due to mistimed peripheral inputs affecting central motor processing, as established in other demyelinating neuropathies. Additionally, the tremor stability index (TSI) was calculated to assess the variability of CIDP-related tremor compared to other tremor disorders.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Anna Kostera-Pruszczyk, Anna Potulska-Chromik, Malgorzata Lukawska, Marta Lipowska, Dorota Hoffman-Zacharska, Beata Olchowik, Magdalena Figlerowicz, Karolina Kanabus, Edyta Rosiak
Summary: Childhood CIDP can manifest in atypical forms in over 50% of cases, including distal, pure motor, or pure sensory variants. While most children have a good prognosis, long-term treatment may be necessary for some patients.
FRONTIERS IN NEUROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Oscar J. Cordero, Carlos Rafael-Vidal, Ruben Varela-Calvino, Cristina Calvino-Sampedro, Beatriz Malvar-Fernandez, Samuel Garcia, Juan E. Vinuela, Jose M. Pego-Reigosa
Summary: Immune system CD4 T-cells with high cell-surface CD26 expression demonstrate anti-tumoral properties, especially when engineered with a chimeric antigen receptor. Different T helper cell subsets show variations in CD26 expression levels, which could impact research on CAR-T cells. The relationship between glycoprotein sCD26 and its enzymatic activity, as well as its correlation with specific T cell subsets, still requires further understanding.
Article
Oncology
Xiao-Dong Mao, Su-Zhu Chen, Su-Qing Shen, Kang-Sheng Liu
Summary: The impact of the immune response on the therapeutic efficacy of neoadjuvant chemotherapy for breast cancer is unclear. This study investigated the correlation patterns of immune cell subsets with the progression of breast cancer during neoadjuvant chemotherapy. The levels of T lymphocyte subsets were influenced by neoadjuvant chemotherapy, and the immune response status varied in different clinical stages.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Clinical Neurology
Mahima Kapoor, Aisling Carr, Martha Foiani, Amanda Heslegrave, Henrik Zetterberg, Andrea Malaspina, Laura Compton, Elspeth Hutton, Alexander Rossor, Mary M. Reilly, Michael P. Lunn
Summary: This study found an association between plasma neurofilament light chain (pNfL) concentration and disease activity in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), suggesting that pNfL concentration may be a useful biomarker for assessing disease remission and relapse.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Marina Romozzi, Giulia Bisogni, Mario Sabatelli, Marco Luigetti
Summary: This study demonstrated that in selected cases it is possible to successfully stop chronic IVIg treatment, even in patients who have been treated for several years.
NEUROLOGICAL SCIENCES
(2021)
Article
Clinical Neurology
Matthew Silsby, Con Yiannikas, Karl Ng, Matthew C. Kiernan, Victor S. C. Fung, Steve Vucic
Summary: Posturography was used to assess balance in CIDP patients receiving IVIg treatment, showing significant improvement in balance. This suggests that posturography can serve as an objective marker of treatment response in clinical management and therapeutic trials.
Review
Biochemistry & Molecular Biology
Yoseph Asmelash Gebru, Haripriya Gupta, Hyeong Seop Kim, Jung A. Eom, Goo Hyun Kwon, Eunju Park, Jin-Ju Jeong, Sung-Min Won, Satya Priya Sharma, Raja Ganesan, Dong Joon Kim, Ki Tae Suk
Summary: NAFLD is characterized by hepatic accumulation of excess lipids, and various T cell subsets and NK cells have been implicated in its progression, with different functions and phenotypes usually leading to proinflammatory effects. The gut microbiota can influence intrahepatic T cell subsets, and NK cells can accumulate in the liver in response to pathogens and tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Fisheries
Belen Alvarez, Concepcion Revilla, Sara Moreno, Angeles Jimenez-Marin, Elena Ramos, Paloma Martinez de la Riva, Teresa Poderoso, Juan J. Garrido, Angel Ezquerra, Javier Dominguez
Summary: This report describes a new monoclonal antibody, 4H5CR4, against porcine CD9, which together with other antibodies can distinguish at least five CD4(+) T cell subsets. The analysis of CD45RA, CD27, CD29, CD95, CCR7, and SLA-DR markers on these subsets reveals a progressive model of CD4(+) T cell development.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Nicholas N. Jarjour, Kelsey M. Wanhainen, Changwei Peng, Noah V. Gavil, Nicholas J. Maurice, Henrique Borges da Silva, Ryan J. Martinez, Talia S. Dalzell, Matthew A. Huggins, David Masopust, Sara E. Hamilton, Stephen C. Jameson
Summary: Interleukin-15 (IL-15) is a central regulator of memory CD8+ T cells and can stimulate their proliferation and expansion. IL-15 sensitivity is an important feature of memory CD8+ T cell populations, with therapeutic potential.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Immunology
Fei Mao, Chao Yang, Weiyu Luo, Yijin Wang, Jie Xie, Hengbing Wang
Summary: This study indicates that PCa patients with lower absolute counts of certain peripheral lymphocyte subsets have a poorer prognosis. The numbers of CD4+ T cells, CD3+ T cells, and NK cells differ significantly between PCa patients at different TNM stages. Univariate and multivariate Cox regression analyses suggest that higher neutrophil numbers, lower CD4+ T cell counts, and lower NK cell counts are unfavorable prognostic factors for PCa patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Clinical Neurology
Namita A. Goyal, Chafic Karam, Kazim A. Sheikh, Mazen M. Dimachkie
Summary: SCIg is a safe and effective alternative option for long-term treatment of CIDP, approved by the FDA in 2018. Evidence suggests that SCIg and IVIg have comparable long-term efficacy in CIDP, but SCIg may offer additional benefits for some patients. Local-site reactions are more common with SCIg, but generally well-tolerated, and many patients prefer SCIg following transition from IVIg.
Review
Immunology
Remi Fromentin, Nicolas Chomont
Summary: The HIV reservoir is not homogenous and is composed of multiple cell types with distinct biological properties. These cells contribute to HIV persistence through specific mechanisms.
SEMINARS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Ilse M. Lucke, Amber Vrijlandt, Johan Lim, Anneke J. Kooi, Ivo N. Schaik, Hans L. Zaaijer, Joppe W. Hovius, Filip Eftimov
Summary: This study found that apparent Bbsl seroconversion often occurs in patients receiving IVIg treatment, but antibodies typically disappear post-treatment, with seroreversion observed in a majority of patients within 3 months. The transient presence of anti-Bbsl IgG antibodies after IVIg treatment appears to be dependent on the brand of IVIg, reflecting variations in Bbsl exposure of plasma donors. Lyme borreliosis serological testing during and after IVIg treatment may be of limited utility.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Robert Fleischmann, Tina Andrasch, Sina Warwas, Rhina Kunz, Stefan Gross, Carl Witt, Johanna Ruhnau, Antje Vogelgesang, Lena Ulm, Annerose Mengel, Bettina von Sarnowski
Summary: This study identified risk factors for the incidence and duration of post-stroke delirium using high-frequency screening. Age, gender, pain, urinary catheter, and post-stroke infection were found to be significant predictors. Insular and basal ganglia lesions also increased the risk of post-stroke delirium.
INTERNATIONAL JOURNAL OF STROKE
(2023)
Article
Clinical Neurology
Frauke Stascheit, Ulrike Grittner, Sarah Hoffmann, Philipp Mergenthaler, Michael Schroeter, Tobias Ruck, Mark Pawlitzki, Franz Blaes, Julia Kaiser, Ulrike Schara, Adela Della-Marina, Andrea Thieme, Tim Hagenacker, Christian Jacobi, Benjamin Berger, Peter P. Urban, Karl Christian Knop, Berthold Schalke, De-Hyung Lee, Petra Kalischewski, Heinz Wiendl, Andreas Meisel
Summary: Current immunosuppressive therapy (IST) increases the severity of COVID-19 in patients with myasthenia gravis, but it does not increase the risk of SARS-CoV-2 infection. Therefore, effective strategies should be implemented to prevent COVID-19 in this high-risk group.
JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Andreas Meisel, Fulvio Baggi, Anthony Behin, Amelia Evoli, Anna Kostera-Pruszczyk, Renato Mantegazza, Raul Juntas Morales, Anna Rostedt Punga, Sabrina Sacconi, Michael Schroeter, Jan Verschuuren, Louise Crathorne, Kris Holmes, Maria-Isabel Leite
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Sarah Hoffmann, Werner Stenzel, Andreas Meisel
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Sarah Hoffmann, Patrick Waters, Leslie Jacobson, Markus Schuelke, Werner Stenzel, Tobias Ruck, Sophie Lehnerer, Frauke Stascheit, Corinna Preusse, Andreas Meisel
Summary: Autoantibody testing is essential for autoimmune myasthenia gravis diagnosis, but about 15% of patients still show negative results (seronegative MG). This study examined the prevalence of clustered AChR, MuSK, and LRP4 autoantibodies in a large German cohort of seronegative MG patients using a live cell-based assay. Out of 67 SNMG patients, 4.5% had clustered AChR autoantibodies, with two patients showing binding to both adult and fetal AChR. None of the patients tested positive for MuSK or LRP4 autoantibodies. Clinical characteristics were similar between patients with and without clustered AChR autoantibodies. Comparisons with a national MG registry showed broad similarities among seronegative MG patients in both cohorts.
NEUROMUSCULAR DISORDERS
(2023)
Article
Clinical Neurology
Frauke Stascheit, Omar Chuquisana, Christian W. Keller, Philip Alexander Ambrose, Sarah Hoffmann, Catharina C. Gross, Sophie Lehnerer, Heinz Wiendl, Nick Willcox, Andreas Meisel, Jan D. Luenemann
Summary: In patients with AChR-Ab(+) MG, there is significantly increased activation of the complement system, which remains present even under standard immunosuppressive therapies but is not evident in patients with MuSK-Abs or seronegative MG. Further exploration of complement inhibition proximal to C5 cleavage is suggested for potential therapeutic benefits in AChR-Ab(+) MG.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Immunology
Dirk Reinhold, Vadim Farztdinov, Yan Yan, Christian Meisel, Henrik Sadlowski, Joachim Kuehn, Frank H. Perschel, Matthias Endres, Emrah Duezel, Stefan Vielhaber, Karina Guttek, Alexander Goihl, Morten Veno, Bianca Teegen, Winfried Stoecker, Paula Stubbemann, Florian Kurth, Leif E. Sander, Markus Ralser, Carolin Otto, Simon Streit, Sven Jarius, Klemens Ruprecht, Helena Radbruch, Jorgen Kjems, Michael Muelleder, Frank Heppner, Peter Koertvelyessy
Summary: Patients with COVID-19 may experience various neurological symptoms, but the role of the central nervous system (CNS) in COVID-19 is still unclear. The inflammatory response in the cerebrospinal fluid (CSF) of COVID-19 patients was studied, and it was found that there were attenuated inflammatory changes compared to patients with herpes simplex virus encephalitis (HSVE). The inflammatory mediators in the CSF of COVID-19 patients were likely derived from the systemic circulation rather than produced within the CNS. Further investigation is needed to understand the relevance of blood-derived mediators of inflammation in the CSF for neurological COVID-19 and post-COVID-19 symptoms.
JOURNAL OF NEUROINFLAMMATION
(2023)
Article
Clinical Neurology
Andreas Meisel, Djillali Annane, Tuan Vu, Renato Mantegazza, Masahisa Katsuno, Rasha Aguzzi, Glen Frick, Laura F. Gault, James Howard Jr
Summary: This study analyzed the interim results of an ongoing open-label extension study to evaluate the long-term treatment effects of ravulizumab in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. The findings showed that ravulizumab demonstrated sustained efficacy and safety in improving the disease condition of patients.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Alexander Nelde, Markus G. Klammer, Christian H. Nolte, Helena Stengl, Michael Kraemer, Regina von Rennenberg, Andreas Meisel, Franziska Scheibe, Matthias Endres, Jan F. Scheitz, Christian Meisel
Summary: This study used data lake-enabled technology to assess post-stroke heart rate and heart rate variability, and found that HR modulation and including HR in machine learning models can improve stroke outcome prediction.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Sarah Dewilde, M. F. Janssen, Nafthali H. Tollenaar, Fiammetta Vanoli, Rita Frangiamore, Glenn Phillips, Sandra Paci, Renato Mantegazza, Andreas Meisel, Frauke Stascheit
Summary: This study aims to assess the concordance between self- and physician-reported MG-ADL scores. The results show that patients and neurologists have a concordant assessment of the patient's MG symptoms when using the MG-ADL scale. This evidence supports patient self-administration of the MG-ADL in clinical practice and research.
Article
Clinical Neurology
Frauke Stascheit, Adela Della Marina, Andreas Meisel
Summary: The treatment of myasthenia gravis is focused on the patient's antibody status. Various therapies including steroids, immunosuppressive treatments, and thymectomy are commonly used. New therapeutic approaches have been developed for patients with acetylcholine receptor antibody and muscle-specific receptor tyrosine kinase antibody. The use of modern immunomodulators based on disease activity is recommended.
Article
Clinical Neurology
Antje Mevius, Lars Joeres, Jutta Biskup, Tanja Heidbrede, Milada Mahic, Thomas Wilke, Ulf Maywald, Sophie Lehnerer, Andreas Meisel
Summary: The aim of this retrospective cohort study was to estimate the prevalence and incidence of myasthenia gravis (MG) in Germany and understand the burden of disease and treatment patterns. The study found that the prevalence of MG in Germany was approximately 39.3/10 0,0 0 0, and the incidence in 2019 was 4.6/10 0,0 0 0. A significant proportion of MG patients remained untreated, and many patients experienced exacerbations or myasthenic crises. MG was associated with higher mortality compared to the general non-MG population.
NEUROMUSCULAR DISORDERS
(2023)
Article
Medicine, General & Internal
Sonia Berrih-Aknin, Jacqueline Palace, Andreas Meisel, Kristl G. Claeys, Srikanth Muppidi, Francesco Sacca, Fatemeh Amini, Mark Larkin, Casey Quinn, Jon Beauchamp, Glenn Philips, Femke De Ruyck, Joyce Ramirez, Sandra Paci
Summary: This study aims to explore the impact of myasthenia gravis (MG) in the real world from a patient perspective. The study included MG patients from different countries and found that despite current treatments, patients still experience a significant burden.
Article
Medicine, Research & Experimental
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Raeuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stuehler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck
Summary: Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis. A combined proteomics and metabolomics approach was used to study a cohort of MG patients treated with eculizumab or azathioprine, as well as treatment-naive patients. Eculizumab was found to modulate the serum proteometabolome, affecting pathways related to oxidative stress, MAP kinase signaling, and lipid metabolism, particularly arachidonic acid signaling.
Article
Multidisciplinary Sciences
Kathrin Goedde, Hella Fuegemann, Ute Goerling, Ulrike Grittner, Raphael Kohl, Andreas Meisel, Thomas Reinhold, Susanne J. Schnitzer, P. Markus Deckert, Nikolaj Frost, Stephan Schreiber, Nina Rieckmann, Christine Holmberg
Summary: This feasibility study aims to evaluate a patient-oriented navigation model that integrates data about barriers to care, vulnerable patient populations, and existing support services. The study consists of two randomized controlled trials and observational cohorts, with the intervention group receiving support from personal navigators for 12 months while the control group receives a brochure with regional support offers. The feasibility of the navigation model is evaluated in terms of acceptance, demand, practicality, and efficacy.
